Lancet seminar: Histiocytosis

Seminar explores pathophysiology and treatment with targeted therapies with BRAF or MEK inhibitors of histiocytosis, a heterogeneous group of rare disorders, characterised by infiltration of almost any organ by myeloid cells with diverse macrophage or dendritic cell phenotypes

Source:

The Lancet